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Method for measuring muscle mass
Abstract
A method for determining muscle mass in a human subject useful for monitoring athletic conditioning,
weight loss programs, nutritional deficiencies, and disease states which cause muscle wasting is provided
comprising administration of a bolus dose of a metabolic marker for 3-methylhistidine, the use of a three-
compartment model to describe data from blood samples collected periodically thereafter, and calculation of
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METHOD FOR MEASURING MUSCLE MASS 
This invention was made, at least in part, with funding 
from the National Institutes of Health (Grants DK-26657, 
DK-20593, RR-00095 and DK-43290) and the United States 
Government may have certain rights therein. 
FIELD OF THE INVENTION 
This invention concerns the field of medicine and athletics 
and involves the administration of a metabolic marker for 
3-methylhistidine to a subject, measurement of plasma con-
centration of marker and 3-methylhistidine over time, and 
use of these measurements to calculate muscle mass by 
means of a 3-compartment mathematical model. 
BACKGROUND OF THE INVENTION 
Techniques to measure body composition are numerous 
and include measurements based on: total body water, total 
body potassium, urinary creatinine excretion, underwater 
weighing (Goldman, R. F. and Buskirk, E. R., "Body volume 
measurement by underwater weighing: description of a 
method", In: Techniques for Measuring Body Composition, 
J. Brozek (ed.), Washington, D.C.: Nat'l Academy of Sci-
ences (1961), 78-79; Lohman, T. G. et al., "Bone and 
mineral measurements and their relation to body density in 
2 
white fibers in skeletal muscle contain the unique amino acid 
3-methylhistidine (Johnson, P. et al., "3-Methylhistidine in 
actin and other muscle proteins," Biochem. J. (1967) 
105:361-370). Following degradation of muscle proteins, 
5 free 3-methylhistidine is released. Yet, 3-methylhistidine is 
not reutilized for protein synthesis because it does not have 
a specific tRNA (Young, V. R. et al, "Metabolism of admin-
istered 3-methylhistidine: Lack of muscle transfer ribo-
nucleic acid charging and quantitative excretion as 
10 3-methylhistidine and its N-acetyl derivative," J. Bioi. 
Chern. (1972) 217:3592-3600). 3-Methylhistidine is quan-
titatively excreted in the urine of man, rat, cattle and rabbit 
(Long, C. L. et al., "Metabolism of 3-methylhistidine in 
man," Metabolism (1975) 24:929-935; Young, V. R. et al., 
15 "Metabolism of administered 3-methylhistidine: Lack of 
muscle transfer ribonucleic acid charging and quantitative 
excretion as 3-methylhistidine and its N-acetyl derivative," 
J. Biol. Chern. (1972) 217:3592-3600; Harris, C. 1 and 
Milne, G., "The urinary excretion of N-tau-methyl histidine 
20 by cattle: validation as an index of muscle protein 
breakdown," Br. J. Nutr. (1981) 45:411-422; Harris, C. I. et 
al., "3-Methylhistidine as a measure of skeletal-muscle 
protein catabolism in the adult New Zealand white rabbit," 
Biochem. Soc. Trans. (1977) 5:706-708). Therefore, it is 
25 thought to be a marker of skeletal muscle protein break-
down. 
children, youth and adults," Hum. Biol. (1984) 56:667-679), Urine 3-methylhistidine estimation of muscle proteolysis 
and neutron activation analysis conductivity and bioelectri- depends on quantitative collection and accurate measure-
cal impedance (Wolfe, R., "Radioactive and stable isotopes ment of urinary 3-methylhistidine. It is assumed that no 
tracers in biomedicine: Principles and practice of kinetic 30 metabolism of 3-methylhistidine occurs in vivo, which is 
analysis," New York: Wiley-Liss (1992) p. 145-165). Of the true in most species (Harris, c. I. and Milne, G., 'The 
current methods available to measure body composition, identification of the N-methyl histidine-containing 
estimates are made of fat and fat free mass (FFM). None of dipeptide, balenine, in muscle extracts from various roam-
the current body composition methods estimate muscle mass mals and the chicken," Comp. Biochem. PhysioL (1987) 
directly. All the methods relate back to underwater weighing 35 86B(2):273-279). However, in the rat 3-methylhistidine is 
which is in turn related to previous limited dissection of transported to liver and is acetylated. The N-acetyl-3-
muscle in human cadavers. Also, such tests only estimate methylhistidine is the major form excreted in the rat (Young, 
lean tissue, which includes bone, liver and skin. v. R. et al., "Metabolism of administered 3-methylhistidine: 
There is great interest in the athletic population in accu- Lack of muscle transfer ribonucleic acid charging and quan-
rately knowing muscle mass. There is also a need for an 40 titative excretion as 3-methylhistidine and its N-acetyl 
accurate method for measurement of muscle mass in order derivative," J. Biol. Chern. (1972) 217:3592-3600), whereas 
to monitor medical conditions such as nutritional deficien- in the adult human, N-acetyl-3-methyl-histidine accounts for 
cies and wasting diseases. less than 5% of the daily 3-methylhistidine excreted (Long, 
There have been many models proposed to measure in C. L. et al., "Metabolism of 3-methylhistidine in man," 
vivo amino acid/protein kinetics. Associated with each 45 Metabolism (1975) 24:929-935). In sheep (Harris, C. I. and 
model are both theoretical and practical problems that must G. Milne, 'The urinary excretion of Nt-methyl histidine in 
be addressed. Noncompartmental models are widely used sheep: an invalid index of muscle protein breakdown," 
but are limited greatly by the necessary assumption that Br.J.Nutr. (1980) 44: 129-140) and pigs (Harris, C. I. and G. 
production does not occur in the sampling compartment into Milne, 'The inadequacy of urinary (N-tau)-methyl histidine 
which the tracer is administered (Cobelli, C. and G. Toffolo. 50 excretion in the pig as a measure of muscle protein 
Compartmental versus noncompartmental modeling for two breakdown," Br .J.Nu tr. ( 19 81) 45:423-42 9) 
accessible pools. Am. J. Physiol. (Endocrinol. Metab.) 247: 3-methylhistidine is not quantitatively excreted in urine but 
R488-R496, 1984). In contrast, compartmental modeling is retained in muscle as a dipeptide balenine (Harris, C. I. 
requires certain physiological assumptions, generally and G. Milne, 'The identification of theN-methyl histidine-
assigning compartments to model various components of a 55 containing dipeptide, balenine, in muscle extracts from 
metabolic system. The model is constructed from an under- various mammals and the chicken," Comp. Biochem. 
standing of the metabolic system under study and is devel- Physiol. (1987) 86B(2):273-279). Hence, urinary 
oped based on relationships between mathematical functions 3-methylhistidine excretion cannot be used to estimate 
describing the isotopic decay curve and the metabolic sys- muscle protein breakdown in these species. 
tern (Wolfe, R., "Radioactive and stable isotopes tracers in 60 A compartmental model for swine or sheep must include 
biomedicine: Principles and practice of kinetic analysis," a compartment for 3-methylhistidine metabolism other than 
New York:Wiley-Liss (1992) 145-165). excretion into a urine compartment Swine excrete less than 
3-Methylhistidine has been used as a noninvasive marker 2% of 3-methylhistidine from muscle metabolism into the 
of muscle proteolysis in vivo (Young, V. R. and H. N. urine with the majority being retained in muscle as the 
Munro, "Nt-Methylhistidine (3-methylhistidine) and muscle 65 dipeptide balenine. Therefore, swine not only have a large 
protein turnover: an overview," Fed. Proc. (1978) pool of free 3-methylhistidine in muscle but also a large 
37:2291-2300). The primary sequence of actin and myosin metabolic "sink" of 3-methylhistidine in the form of bale-
5,628,328 
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nine. Likewise, sheep excrete approximately 15% of 14:248-251. Nishizawa et al. (Nishizawa, M. et al., "Frac-
3-methylhistidine in the urine with the remainder being tional catabolic rates of myosin and actin estimated by 
retained in muscle as the dipeptide balenine. Hence a urinary excretion ofN-methyl histidine: the effect of dietary 
compartmental model describing the metabolism of protein level on catabolic rates under conditions of restricted 
3-methylhistidine in these two species must incorporate 5 food intake," Br. J. Nutr. (1977) 37:345-353) concluded that 
these metabolic differences as compared to humans, cattle, the skin and intestine contributed up to 10% of the total body 
rats and rabbits. Although there is a substantial body of pool of 3-methylhistidine. Comparative turnover studies of 
literature on the metabolism of 3-methylhistidine, few 3-methylhistidine-containing proteins in intestine, skin and 
reports have actually measured daily variability of endog- skeletal muscle suggest that the skin and the intestine 
enous 3-methylhistidine excretion. Lukaski et al. (Lukaski, 10 contributed 17% of the 3-methylhistidine excreted per day in 
H. C. et al., "Relationship between endogenous the urine (Millward, D. J. and P. C. Bates, 
3-methylhistidine excretion and body composition." Am. J. "3-Methylhistidine turnover in the whole body, and the 
Physiol. (Endocrinol. Metab.)(1981) 240(3):E302-E307) contribution of skeletal muscle and intestine to urinary 
reported an intra-individual coefficient of variation of 4.5% 3-methylhistidine excretion in the adult rat," Biochem. J. 
(range 2.2 to 7.0%). Similar intra-individual variation (5%) 15 (1983) 214:607-615). These calculated values are based on 
was reported by Sjolin et al. (Sjolin, J. et al., "Urinary the fitting of exponential regression lines to the specific 
excretion of 1-methylhistidine: A qualitative indicator of activity of 3-methylhistidine from the various tissues after 
exogenous 3-methylhistidine and intake of meats from vari- giving a dose [methyl-3H]methionine. The accuracy of this 
ous sources," Metabolism (1987) 36:1175-1184), whereas estimate is uncertain because the labeling technique used 
interindividual variation (20%) is usually of a much higher 20 may be confounded by the reutilization of labeled methion-
magnitude even with large and homogeneous subject popu- ine (Young, V. R. and H. N. Munro, "Nt-Methylhistidine 
lations (Sjolin, J. et al., "Urinary excretion of (3-methylhistidine) and muscle protein turnover: an 
1-methylhistidine: A qualitative indicator of exogenous overview," Fed. Proc. (1978) 37:2291-2300). Millward et 
3-methylhistidine and intake of meats from various al. (Millward, D. J. et al., "Quantitative importance of 
sources," Metabolism (1987) 36:1175-1184). 25 non-skeletal-muscle sources of N-tau-methyl-histidine in 
A relationship between fat free mass and urinary urine," Biochem. J. (1980) 190:225-228) have also con-
3-methylhistidine has been demonstrated in humans eluded that skeletal muscle, skin, and gastrointestinal tract 
(Lukaski, H. C. and Mendez, J., "Relationship between contribute only 25, 7 and 10%, respectively, of the 
fat-free weight and urinary 3-methylhistidine excretion in 3-methylhistidine excreted in the adult rat, with the remain-
man." Metabolism (1980) 29:758-761; Lukaski, H. C. et al., 30 der being excreted by some unknown organ. These values 
"Relationship between endogenous 3-methylhistidine excre- were based on a measurement of a decay curve of labeled 
tion and body composition," Am. J. Physiol. (Endocrinol. 3-methylhistidine, after an injection of labeled methionine. 
Metab.) (1981) 240(3):E302-E307; Mendez, J. et al., ''Fat- In contrast, following a duodenoileostomy in rats which 
free mass as a function of maximal oxygen consumption and left only 8% to 10% of small gut intact, it was concluded that 
24-hour urinary creatinine, and 3-methylhistidine 35 the small intestine did not make a significant contribution to 
excretion," Am. J. Clin. Nutr. (1984) 39:710-714). Urinary a 24-hour urinary excretion of 3-methylhistidine (Brenner, 
creatinine has been suggested as an index of muscle mass U. et al., "The contribution of small gut to the 
and strong correlations have been demonstrated between 3-methylhistidine metabolism in the adult rat," Metabolism 
urinary creatinine and 3-methylhistidine excretion (r-=0.87, (1987) 36:416-418). A similar study with short-bowel 
P<0.001) and between urinary creatinine and muscle mass 40 humans indicated that skeletal muscle was the major source 
(Lukaski, H.C et al., "Relationship between endogenous of urinary 3-methylhistidine. In human patients with varying 
3-methylhistidine excretion and body composition," Am. J. degrees of infection (Sjolin, J. et al., "Exchange of 
Physiol. (Endocrinol. Metab.) (1981) 240(3):E302-E307). 3-methylhistidine in the splanchnic region in human 
Previous studies have attempted to validate the quantitative infection," Am. J. Clin. Nutr. (1989) 50:1407-1414) it was 
urinary excretion of 3-methylhistidine. 14C-labeled 45 concluded that urinary 3-methylhistidine was a valid marker 
3-methylhistidine was injected, but its isotopic dilution was of myofibrillar protein breakdown because it was correlated 
not described (Long, C. L. et al., "Metabolism of with the release of 3-methylhistidine from the leg. 
3-methylhistidine in man," Metabolism (1975) Furthermore, it was later shown with additional patients 
24:929-935). (Sjolin, J. et al., '"Total and net muscle protein breakdown in 
There is a controversy as to whether urinary 50 infection determined by amino acid effluxes," Am. J. 
3-methylhistidine is primarily a product of skeletal muscle Physiol. (Endocrinol. Metab.) (1990) 258:E856-E863) that 
protein turnover or whether other tissues might contribute a there was a significant linear relationship between the 
significant amount to the daily production. Haverberg et al. effluxes of tyrosine and phenylalanine and the efflux and 
(Haverberg, L. N. et al., "Nt-Methylhistidine content of urinary excretion of 3-methylhistidine. 
mixed proteins in various rat tissues," Biochem. Biophys. 55 A method to describe 3-methylhistidine metabolism in 
Acta (1975) 405:67-71) showed that the mixed proteins in cattle has been described by using a compartmental model 
all of the organs sampled contained detectable levels of (Rathmacher, J. A. et al., '"Technical Note: The use of a 
bound 3-methylhistidine. However, when examining each compartmental model to estimate the de novo production 
organ as a whole, it was found that skeletal muscle contained rate of Nt-methylhistidine in cattle," J. Anim. Sci. (1992) 
the majority (98%) of the total amount. This study did not 60 70:2104-2108). The model showed similar results from 
include an assessment of the amount of 3-methylhistidine in plasma and urine. The model estimated 3-methylhistidine 
skin and intestine. Intestinal tissue is also a source of production. Fractional muscle breakdown was calculated 
3-methylhistidine production in humans as measured in from the production rate by assuming that muscle mass 
urine. Brenner, U. et al. (1987), "Der Ein:fluss des accounted for 33% of total mass of the steers. (Rathmacher, 
Dunndarrns auf den 3-Methylhistidin-sta:ffwechsel des Men- 65 J. A. et al., 'Technical Note: The use of a compartmental 
schen (The effect of the small intestine on 3-methylhistidine model to estimate the de novo production rate of 
metabolism in the human)", Infusionther. Klin. Ernahr. Nt-methylhistidine in cattle," J. Anim. Sci. (1992) 
5,628,328 
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As an alternative to measuring urinary 3-methylhistidine, 
the difference between plasma 3-methylhistidine measure-
ments of venous and arterial flows in humans has been used 
to determine 3-methylhistidine afflux in patients with myo-
70:2104-2108). Cattle quantitatively excrete 
3-methylhistidine into the urine, as do humans (Harris, C. 1 
and Milne, G., ''The urinary excretion of N-tau-methyl 
histidine by cattle: validation as an index of muscle protein 
breakdown," Br. J. Nutr. (1981) 45:411-422). 
3-methylhistidine production can be described by the model. 
s tonic dystrophy; this difference was found not to correlate 
with the presence of myotonic dystrophy, suggesting that 
myofibrillar protein degradation is not increased in myotonic 
dystrophy. 
A three-compartment mathematical model for analysis of 
plasma measurements of isotopic and natural 
3-methylhistidine in lambs has been tested, resulting in the 
suggestion that pool (compartment) 3 may be a valid indi- 10 
cator of muscle mass in sheep. (Link, G. A. (1991), "A 
comprehensive approach to describing protein turnover in 
lambs," Ph.D. thesis, Department of Animal Science, Iowa 
State University.) However, sheep metabolize 
3-methylhistidine differently than humans, i.e., not all of it 
is excreted in the urine but, as discussed above, part is 15 
All publications referred to herein are incorporated in 
their entirety by reference. 
There is thus a need in the art for the measurement of 
muscle mass in humans which has greater accuracy and is 
subject to less interference by extraneous factors than prior 
art tests. 
converted to balenine and stored in the muscles. BRIEF DESCRIPTION OF THE DRAWINGS 
A similar kinetic approach can be utilized in sheep and FIG. 1. Schematic of a 3-compartment model used to 
swine (Rathmacher, J. A. et al., "Measurement of al th ki ti fdi tri'b ti' t b li dd 
3 h lh . 'd' d · . 1 b b . an yze e ne cs o s u on, me a o sm, an e novo 
-met y iStl me pro uctwn m am s y usmg od cti f 3 th 1hi tidin (3 th 1hi tidin ) M compartmental-kinetic analysis," Br. J. Nutr. (1992) 20 pr u on ° -me Y s e -me Y s . .e: .1' 
69:743-755; Rathmacher, J.A. et al., "Estimation of M2, and M3 represent the mas~ of 3-methylhistidine m 
3-methylhistidine production in swine by compartmental compartments 1, 2 and 3, respectively. L2,1, L1,2, Lo,1• L3,2• 
analysis," J. Anim. Sci. (1992) Abstract, 70:194) which, and L2,3 . ~e. frac~o~al transfer rate coefficient~ of 
unlike humans, retain 3-methylhistidine in muscle as the 3-methylhistidine Within the system. The tracer, 3-[ H3-
dipeptide balenine (Harris, C. 1 and Milne, G., ''The urinary 25 methyl]-methylhistidine (D3-3-methylhistidine), was 
excretion of Nt-methyl histidine in sheep: an invalid index injected into compartment 1. Sampling was performed from 
of muscle protein breakdown," Br. J. Nutr. (1980) compartment 1. De novo production of 3-methylhistidine 
44:129-140; Harris, C. 1 and Milne, G., ''The inadequacy of was into compartment 3. 
urinary (N-tau)-methyl histidine excretion in the pig as a FIG. 2. Disappearance of tracer, 3-[2H3-methyl]-
measure of muscle protein breakdown," Br. J. Nutr. (1981) 30 methylhistidine, as a ratio of 3-[2H3-methyl]-
45:423-429). methylhistidine:3-methylhistidine in plasma as described by 
Muscle is degraded in response to many metabolic situ- the 3-compartment model of 3-methylhistidine. Symbols 
ations including: starvation, infection, surgery, diabetes, (.._)represent observed data, and the line(-) represents best 
nutrition level, hormonal and stress conditions. Scientific fit generated by the model. 
~dvances in these cli~cal areas are ~ted due to ~tations 35 FIG. 3A: Daily 3-methylhistidine production expressed as 
m me~odology availa~le to quantitate myofibrillar pr'; J.IID.Ol· kg-1.d-1 for each individual subject and a mean off our 
teolys1s versus proteolysis of ~uscle as a whole. The ~o!em individuals as calculated from urinary excretion (hatched 
rese~e of skele~ muscl~ iS composed of two distinct bars) and by a 3-compartment model of 3-methylhistidine 
fractions; m~ofibrillar protem, the structural component, ~d production (solid bars). There was no mean difference 
non-my~fibrillar, non-structural component. The my~fibril- 40 between urinary and model 3-methylhistidine production, 
lar protem makes up 60% of the s~eletal m~scle protem and P>0.30. FIG. 3B: Daily 3-methylhistidine:creatinine ratio, 
turn?ver slow~ than non.-myofibrillar protem ~Bates, P. C: et J.IID.Ol·mg-1 for each individual subject and a mean of the 
al., 'Myofibrillar protem turnover: synthesis of protem- four individuals as calculated from urinary excretion 
bound 3~methylhistidine, acti~, myosin heavy chain an~ (hatched bars) and by a 3-compartment model of 
al~olase m rat skeletal muscle m the fed a~d starve~ states, 45 3-methylhistidine production (solid bars). There was no 
B10chem. J. (1983).214:593-605). There _IS also eVIdence to mean difference between urinary and model 
show that myofibrillar and non-myofibrillar are not under 3-methylhistidine:creatinine ratio, P>0.30. 
the s~e metabolic control n~~ degra~ed by the s~e FIG. 4A-C. A comparison of 3-compartment model struc-
mech.amsm (Lo~ell, .B. B. et al., Regulation °~ myo~brillar tures of 3-methylhistidine metabolism among cattle 
protem degradation m rat skeletal muscle dunng bnef and 50 • ' 
prolonged starvation," Metabolism (1986) 35:1121_1127; humans, sheep and swme. FIG. 4A shows the model useful 
Lo 11 B B al "E 'd th t 1 t for cattle and humans. FIG. 4B shows the sheep model and 
. we ' . · · et ., . V1 ence a . ysosome~ ar~ no FIG. 4C shows the swine model. 
mvolved m the degradation of myofibrillar protems m rat 
skeletal muscle," Biochem. J. (1986) 234:237-240; 
Goodman, M. N., "Differential effects of acute changes in 
cell Ca2+ concentration on myofibrillar and non-
myofibrillar protein breakdown in the rat extensor digitorum 
longus muscle in vitro: Assessment by production of 
tyrosine and N-tau-methylhistidine," Biochem. J. (1987) 
FIG. 5. A plot of muscle mass as predicted by the method 
55 of this invention compared to observed muscle mass in 
swine. 
241:121-127). 60 
An insignificant increase in 3-methylhistidine excretion in 
humans during exercise and a significant increase during 
recovery from exercise has been reported, suggesting that 
exercise does not result in significant depletion of muscle 
mass. Carraro, F. (1990), "Effect of exercise and recovery on 65 
muscle protein synthesis in human subjects," Am. J. Physiol. 
259E470-476. 
FIG. 6. A plot of fat-free mass determined by the method 
of this invention as compared to fat free mass as determined 
by underwater weighing. 
SUMMARY OF THE INVENTION 
A method for determining muscle mass in a human 
subject is provided. The method may be used for monitoring 
athletic conditioning, weight loss programs, nutritional 
deficiencies, and disease states which cause muscle wasting 
such as muscular dystrophy. The method involves adminis-
tration of a bolus dose of a metabolic marker (also called 
5,628,328 
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"tracer" herein) for 3-methylhistidine and the use of a 
three-compartment kinetic model to describe data collected 
from blood samples collected periodically thereafter. 
8 
erably by gas chromatography mass spectroscopy utilizing 
1,1-e80 2)1-methylhistidine as an internal standard (meat 
diet) or 1-methylhistidine as an internal standard (meat-free 
diet). 
A three-compartment mathematical model is then gener-
ated from these measurements, preferably using a 
Simulation, Analysis and Modeling (SAAM) computer pro-
gram as more fully described hereinafter. The three-
compartment mathematical model of this invention is 
An important advantage of the compartmental model is 
that it provides additional information about the metabolism 5 
and distribution of 3-methylhistidine which urinary 
3-methylhistidine measurements cannot provide. This 
method does not necessitate quantitative urine collection; 
reduces error due to the frequency of plasma sampling vs. 
the infrequency of urine collection; and in providing detailed 
information about compartment size and transfer rates, 
allows more accurate and efficient determinations of muscle 
mass than previously-known methods. 
10 depicted in FIG. 1. Applicants have discovered that the 
three-compartment model most accurately and simply 
describes the system and provides data for accurate mea-
surement of muscle mass. A two-compartment model was 
found to be inadequate, while little or no gain in accuracy The method of this invention for measuring muscle mass in a human subject comprises: 
(a) obtaining the total body weight of the subject; 
(b) administering to said subject a known amount of a 
metabolic marker for 3-methylhistidine; 
(c) periodically removing blood or urine samples from 
said subject and recording the time to the nearest 
second; 
15 was obtained using a four-compartment model. While the 
compartments are not literally described as corresponding to 
particular locations in the body, applicants have determined 
that compartment 1 (M1) may be roughly thought of as 
corresponding to the plasma and extracellular space and 
(d) measuring the amount of said marker and of 
3-methylhistidine in each such sample; 
20 compartments 2 (M2) and 3 (M3) may be roughly thought of 
as corresponding to intracellular space (within the muscles). 
(e) generating a three-compartment mathematical model 
from said measurements comprising values for the 
functional transfer rates in and out of said 
compartments, values for the mass of 3-methylhistidine 
Muscle mass may be calculated using values generated 
from using the three-compartment model. Muscle mass may 
be calculated using total body weight and the mass of 
25 3-methylhistidine in compartment 2 by the equation: 
in each compartment and values for the mass transfer 
rates of 3-methylhistidine in and out of said compart-
ments; 30 
Muscle (kg)=-31.96+D.0000027(M2)+0.80 (wt) 
where 
M2 is the mass of 3-methylhistidine in compartment 2. 
and wt is body weight (kg). (f) calculating muscle mass as a function of the numerical 
value of at least one of said values and the total body 
weight of the subject. 
As used herein, M 1 , M2 AND M3 are mass of 
3-methylhistidine in nmol; Rii is the mass transfer rate in 
nmollmin; and Lii is the fraction/min transferred. 
Alternatively, muscle mass may be calculated using the 
fractional transfer rate of 3-methylhistidine from compart-
ment 1 into urine and the mass of 3-methylhistidine in 
35 compartment 2 using the equation: 
Metabolic markers for 3-methylhistidine may be any 
markers known to the art including radioactive isotopes of 
3-methylhistidine such as 14C-labelled 3-methylhistidine, 
and stable, non-radioactive isotopes of 3-methylhistidine 40 
such as 3-[ 2 H3 -methyl]-methylhistidine (03 -3-
methylhistidine) and 3-[13C]methylhistidine. 0 3 -3-
methylhistidine is a preferred marker of this invention. 
Administration may be oral or intravenous, and is pref-
erably intravenous. Any site may be used for administration 45 
of the marker, as is known to the art. 
The amount of marker administered should be between 
about 0.2 nmollkg and about 0.8 nmollkg body weight, 
preferably between about 0.2 and about 0.6, and most 
preferably between about 0.2 and about 0.3. When admin- 50 
istered orally, the does is usually at the higher end of the 
range. 0 3-3-methylhistidine administered in such small 
quantities is non-toxic and is quantitatively excreted in 
urine. 
Blood or urine samples are periodically taken from the 55 
patient, as is known to the art, preferably in an amount of 
between about 2.5 and about 10 mL per sample. Samples are 
preferably taken over a period sufficient to achieve steady 
state decay. Generally, samples should be taken over a 
period of at least about 48 hours, preferably between about 60 
48 and about 72 hours, and more preferably about 60 hours. 
At least about 12 blood or urine samples should be taken 
over this period, preferably evenly spaced over the period. 
More preferably between about 10 and about 18 samples are 
taken, and most preferably about 14 samples are taken. 65 
The amount of marker and 3-methylhistidine in each 
sample is measured by any means known to the art, pref-
Muscle (kg)=-9.90+3039.5(L,,1)+0.000155(M2) 
where 
L0 1 is the fractional transfer rate (min-1 ) for 
3-methylhistidine from compartment 1 (M1) into urine 
(0), and M2 is the mass of 3-methylhistidine in com-
partment 2 (nmol). 
Additional accuracy is possible when body weight is also 
used to calculate muscle mass. The following equation is 
used: 
Muscle mass (kg)=-32.39 -0.00035(M2)-783.194(L0,1)+0.927 
(wt) 
where wt is body weight (kg). 
Additional accuracy is possible when the mass transfer 
rate of 3-methylhistidine from compartment 2 into compart-




R1,2 is the mass transfer rate from compartment 2 to 
compartment 1 (nmol·min-1). 
Alternatively, muscle mass is calculated as a function of 
the following values: L1,2 , L0 ,1, M1, ~.3 and wt using the 
equation: 
where 




L1,2 is the fractional transfer rate of 3-methylhistidine 
from compartment 2 to compartment 1 (min-1), 
L0,1 is the fractional transfer rate of 3-methylhistidine 
from compartment 1 into urine (0) (min-1), 
M1 is the mass of 3-methylhistidine in compartment 1 
(nmol), and 
R2.3 is the mass transfer rate of 3-methylhistidine from 
compartment 3 to compartment 2 (nmol·min-1). 
Prior to testing, the subject is preferably placed on a 
meat-free diet for at least about 72 hours. Alternatively, the 
subject may be asked to fast for at least about 12 hours prior 
to the test. Preferably, meat is excluded from the diet for at 
least about three days and the subject is asked to fast 
overnight prior to the test. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
A preferred method of measuring muscle mass provided 
herein involves administration of a bolus dose of D3-3-
methylhistidine of about 0.20 J.l1lllkg administered intrave-
nously into the foreann vein of the dominant ann. Blood 
samples are taken at regular intervals over a twelve hour 
period, more frequently during the first 90 minutes, e.g. at 0, 
2, 5, 10, 15, 30, 45, and 90 minutes, followed by further 
samples at 150, 210, 270, 330, 720, 1440, 2160, 2880 and 
3600 minutes. 
The concentrations of 3-methylhistidine and D3-3-
methylhistidine are measured by gas chromatography mass 
spectroscopy in each sample, and the ratio of isotopic to 
natural 3-methylhistidine in each sample entered into a 
SAAM modeling program on personal computer to generate 
10 
catheter was inserted into the contralateral foreann vein for 
the infusion of L-3-[methyl-2H3]-histidine (MSD Isotopes, 
Montreal, Canada). Finally, another catheter was threaded 
retrograde into the brachial vein of the dominant ann and 
5 used for sampling of the foreann tissue. 
Each study was four days in duration. Starting at t=O (8.00 
hours), subjects were administered a bolus infusion of 
L-3-[methyl2H3]-histidine (D3-3-methylhistidine) at 0.13 
J.IffiOI/kg into the foreann vein of the dominant arm. The 
10 infusate was passed through a Millex-GS sterilizing filter (0.22 Jllll; Millipore Products Divisions, Bedford, Mass.) 
before the infusion. Blood samples were obtained from the 
superficial hand vein and from the deep foreann vein at 0, 
1, 2, 5, 10, 15, 30, 45, 90, 150, 210, 270, 330, and 720 min. 
postinjection. During this time, the subjects were required to 
15 stay at the Clinical Research Center, although they were 
allowed to ambulate freely within their rooms. Free access 
to food and drink was allowed after the 330-min sample. 
After 720 min, the catheters were removed and the patients 
were allowed to go home. For the following three days, the 
20 subjects returned to the CRC each morning before eating for 
further blood sampling by percutaneous venous puncture at 
1,440, 2,880, and 4,320 min postinjection. Urine was col-
lected over 24 hour periods the day before and for three days 
after tracer infusion. 
25 Blood was collected in heparinized syringes, transferred 
to tubes containing N~EDTA (15 mg/tube), and centri-
fuged. The plasma obtained was immediately placed on ice. 
An aliquot of the plasma was processed for determination of 
3-methylhistidine concentration as well as the L-3-[methyl-
30 2H3]-histidine:3-methylhistidine isotope enrichment. The 
remainder of the plasma was frozen at -70° C. The urine 
obtained was processed for the determination of creatinine 
both as a measure of the completeness of the collection a three-compartment model. The three-compartment model 
provides values for the mass of 3-methylhistidine in each 
compartment and for the mass transfer rates of 35 
3-methylhistidine in and out of each compartment. 
(Pencharz, P. B. et al., 'The effect of an energy-restricted 
diet on the protein metabolism of obese adolescents: nitro-
gen-balance and whole-body nitrogen turnover," Clin. Sci. 
(1980) 59:13-18), and for the estimation of lean body mass 
(Blackburn, G. L. et al., "Nutritional and metabolic assess-
ment of hospitalized patients," J. Parenter. Enteral. Nutr. 
The values are then used to calculate muscle mass for 
each subject. 
EXAMPLE 1 40 (1977) 1:11-22). Urinary 3-methylhistidine concentration 
and production were also measured (Rathmacher, J. A. et al., 
Determination of Fat Free Mass as a Function of M2 • "Gas chromatographic-mass spectrometric analysis of stable 
Normal volunteers with no evidence or history of diabetes isotopes of 3-methylhistidine in biological fluids: awlica-
mellitus or of cardiac, liver, renal or pulmonary diseases tion to plasma kinetics in vivo," Bioi. Mass Spectrom. 
were studied. The subjects consisted of 3 males and 1 45 (1992) 21:560-566). 
female, ranging in age from 31 to 37 years, in body weight Body composition was determined for each subject from 
from 47 to 92 kg, and in body mass index (BMI) from 19.2 the measurements of body density estimated by underwater 
to 25.5. The purpose and possible risks of the study were weighing (Goldman, R. F. and Buskirk, E. R., "Body volume 
explained to all subjects, and their voluntary written consent measurement by underwater weighing: description of a 
was obtained. The study protocol was approved by the 50 method," In: Techniques for measuring body composition, J. 
Committee for the Protection of Human Subjects of the Brozek (ed) Washington D.C., National Academy of Sci-
Institutional Review Board at Vanderbilt University School ences (1961) 78-79). Body weights in air and underwater 
of Medicine. All studies were performed at the Clinical were measured to the nearest 25 g by using Detecto (Webb 
Research Center (CRC). Subjects were placed on balanced City, Mo.) and Chatilion Spring (New Gardens, N.Y.) scales, 
weight-maintenance diets for at least one week before the 55 respectively. Residual lung volume was determined (simul-
start of the study. Meat was excluded from the subjects' diets taneously with underwater weighing) with a closed-circuit, 
for three days before the study and during the study. nitrogen-dilution method (Pencharz, P.B. et al., 'The effect 
All studies were performed after a 10-12 hour overnight of an energy-restricted diet on the protein metabolism of 
fast. On the morning of the experiment ( 6.30 to 7.00 hours), obese adolescents: nitrogen-balance and whole-body nitro-
an 18-gauge Angiocatheter™ (Benton Dickinson, Sandy, 60 gen turnover," Clin. Sci. (1980) 59:13-18). Nitrogen con-
Utah) was placed in a superficial hand vein of the nondomi- centration during rebreathing was measured with a Med-
nant ann for blood sampling. The hand was heated to 55° C. Science 505-D Nitralizer (St. Louis, Mo.). The percentage of 
to ensure complete arterialization (Abumrad, N.N. et al., body fat was estimated from body density by using the 
"Use of a heated superficial hand vein as an alternative site revised equation of Lohman et al. (Lohman, T. G. et al., 
for the measurement of amino acid concentrations and for 65 "Bone and mineral measurements and their relation to body 
the study of glucose and alanine kinetics in man," Metabo- density in children, youth and adults," Hum. Biol. (1984) 
lism (1981) 30:936-940). In addition, a 16-gauge angio- 56:667-679). 
5,628,328 
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The enrichment of D3-3-methylhistidine was quantitated 
in blood over time. The baseline enrichment was subtracted 
from experimental samples. D3-3-methylhistidine decay 
from plasma was evaluated using a compartmental model 
developed through the use of the Simulation, Analysis and 
Modeling program (SAAM/CONSAM-31.0~) (Berman, M. 
and Weiss, M. F., SAAM Manual, US Department of HEW 
Publication No. (NTII) 78-180. US GPO, Washington, D.C. 
(1978), incorporated herein by reference; Boston, R. C. et 
al., "Conversational SAAM-an inter-reactive program for 
kinetic analysis of biological systems," Comp. Prog. 
Biomed (1981) 13: 111, incorporated herein by reference) on 
a personal computer. The model, illustrated in FIG. 1, was 
configured by entering the isotope ratio in plasma of the 
D3- 3-methylhistidine:natural 3-methylhistidine into com-
partment 1 over time as described for models using stable 
isotope kinetic data (Cobelli, et al., "Models to interpret 
kinetic data in stable isotope tracer studies," Am. J. Physiol. 
(Endocrinol. Metab.) (1987) 253:E551-E564). The ratio 
was standardized by dividing the isotope ratio by the dose of 
tracer in the bolus injection. The model was solved using 
SAAM and allowed to converge on the observed tracer data, 
and produced transfer coefficients that minimized the 
weighted total sum of squares between observed and calcu-
lated data points. Model code 10, which uses a set of linear 
differential equations having constant coefficients, was used 
to explain the tracer data A minimum of three compartments 
were needed to accurately describe the kinetics and metabo-
lism of 3-methylhistidine. The model consisted of three 
compartments or pools of 3-methylhistidine; the only exit 
from model was out of pool 1. A steady-state solution was 
also obtained and initialized by setting the mass of com-
partment 1 equal to the mean concentration of natural 
3-methylhistidine in the plasma multiplied by the space of 
distribution in compartment 1. Compartmental masses and 
flux of 3-methylhistidine between compartments were also 
acquired. 
In this model, compartment 1 is assumed to represent 
plasma and extracellular fluid, while compartments 2 and 3 
are probably tissue pools of intracellular 3-methylhistidine. 
The predicted irreversible loss into urine from compartment 
1 was derived from the de novo production of 3-methylhis-
tidine as it appears into an intracellular tissue compartment 
3. 
Steady state masses and transport rates were calculated, 
and the de novo production rate was calculated and used to 
calculate a fractional degradation rate for the myofibrillar 
proteins. Steady state calculations were initialized by mul-
tiplying plasma 3-methylhistidine concentration (nmol/mL) 
by the initial space of compartment 1. The initial space of 
distribution is calculated experimentally from the kinetic 
data as a proportionality constant. The remainder of com-
partment masses and fluxes of 3-methylhistidine were 
resolved form the three differential equations that describe 
the model. No meat was fed to the subjects, so the only 
source of 3-methylhistidine entering the model was from de 
novo production which is depicted in the model as an arrow 
into compartment 3. Models were evaluated by performing 
an F test on the sum of squares for each model (Jones, R.H. 
12 
based calculations were compared by at-test (Steele, R.G.D. 
and Torrie, J. H., Principles and Procedures of Statistics: A 
Biofnetrical Approach, New York: McGraw-Hill Book Co., 
1980). Pearson correlation coefficients were used to evaluate 
5 the relationship between model parameters and body com-
position using the SAS statistical software (SAS Inst., Inc., 
Cary, N.C.). 
Table 1 presents measurements of body composition, 
including estimates of fat (kg), body mass index, kg/m2 
10 (BMI), % fat, and fat free mass (FFM, kg) for each indi-
vidual subject. Lean body mass was correlated to compart-
ments of the model (Table 3). The compartment 2 mass (M2• 
nmoles) was positively correlated with FFM (P=0.9), and 
the model estimate of 3-methylhistidine production was 
15 correlated with FFM but not significantly (r=0.74, P=0.25), 
whereas urinary creatinine was not correlated with FFM 
(r-=0.36, P=0.64). BMI and fat were positively correlated 
with M3 (P=0.16 and P=0.08). 
Plasma levels of 3-methylhistidine did not change over 
20 the four days of the study, so steady state was assumed. A 
representative decay of D3 _3-methylhistidine:3-methylhisti-
dine is presented in FIG. 2. The decay curve is characterized 
by a rapid decrease in the D3_3-methylhistidine:3-methyl-
histidine ratio during the first 5 hours followed by a slow 
25 linear (sernilog plot) decay over the three days of blood 
sampling. 
The kinetic model parameters (Lii) are presented in Table 
2. Variations of the parameters were evaluated by the 
coefficient of variation (%CV=100xSD+mean) of each indi-
30 vidual parameter. Ranges for %CV were from 16 to 43% for 
L 2•1 , 24 to 46% for L 1,2 , 9 to 136% for Lo.1 , 12 to 49% for 
L 3 2 , and 15 to 115% for L 2 3• These parameters were within th~ acceptable range, except for L 0•1 and L 2,3 of subject A 
which were above 100%. A %CV greater than 100% is not 
35 acceptable for a model parameter estimation (Wolfe, Robert 
R., Radioactive and Stable Isotopes Tracer in Biomedicine: 
Principles and Practice of Kinetic Analysis, New York: 
Wiley-Uss (1992) 145-165). In previous studies using 
cattle, the %CV's for the Lii were less than 50%. The larger 
40 %CV for parameters L0 •1 and L2•3 , particularly for subject A, 
may be explained by too few points between 300 and 1440 
min; additional data points will be needed to lower the 
variation. The 3-methylhistidine model compartment mass 
(Mi) and mass transfer rates (Rii) are presented in Table 2. 
45 Compartment 2 is 1.5 times larger than compartment 1, and 
compartment 3 is 13 times larger than compartment 1. 
The calculated de novo production rate of 3-methylhisti-
dine and the nrinary 3-methylhistidine excretion is presented 
in FIG. 3 expressed as J.lillOl-kg-1·d-I, and they were also 
50 expressed as a 3-methylhistidine:creatinine ratio (J.Iillol·rng-
1). In both cases the model estimate of 3-methylhistidine 
production was not different (P>0.30) from urinary 3-me-
thylhistidine production. Urinary 3-methylhistidine produc-
tion was lower than the model estimate of 3-methylhistidine 
55 production in each subject, but these variables were highly 
correlated (r-=0.97, P=0.033). 
et al., "Statistical identification of compartmental models 
with application to plasma protein kinetics," Comp. Biomed. 60 
Res. (1984) 17:277-288). Individual model parameters were 
evaluated by the coefficient of variation. A coefficient of 
variation of less than 50% was determined adequate for each 
parameter. 
Table 3 presents the relationship of model parameters to 
urinary 3-methylhistidine and body composition and shows 
M2 to be highly correlated to fat free mass. 
An objective of the present study was to determine 
whether a de novo production rate of 3-methylhistidine as 
estimated by the isotope model was similar to urinary 
3-methylhistidine production. The slope of curve (FIG. 2) 
was similar to that of other species evaluated with this model 
Values are presented for each individual subject as well as 
mean ±SE. Means for 3-methylhistidine production and for 
3-methylhistidine to creatinine ratio for model- and urine-
65 (Rathmacher, J.A. et al. (1992), 'Technical Note: the use of 
a compartmental model to estimate the de novo production 
rate of N-methylhistidine in cattle," J. Anim. Sci. 
5,628,328 
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A. et al. ( 1992), ''Technical Note: the use of a compartmental 
model to estimate the de novo production rate of N-meth-
ylhistidine in cattle," J. Anim. Sci. 70:2104-2108) where 
model and urinary 3-methylhistidine production results were 
70:2104-2108; Rathmacher, J. A. et al. (1993), "Measure-
ment of 3-methylhistidine production in lambs by using 
compartmental-kinetic analysis," Brit J. Nutrition 
69:743-755; Rathmacher, J. A. et al., "Estimation of 3-me-
thylhistidine production in swine by compartmental analy-
sis," J. Anim. Sci. (1992) 70:194 (Abstract)). The in vivo 
kinetics of 3-methylhistidine in human subjects can be 
described by means of a simple serial model of 3-compart-
ments and sampling of only plasma. The kinetic parameters, 
L;j, compartment mass M; and mass transfer rates Rij are 
presented as a reference for future modeling of 3-methyl-
histidine metabolism. 
5 similar but tended to be higher than urine values. This could 
be due to minor losses in urine or small amounts of 3-me-
thylhistidine metabolism/conjugation in humans. 
10 TABLE 1 
Subject characteristics 
15 Subjects 
Parameter A B c D 
20 
Age, years 35 37 31 31 
Sex 0 !i! 0 0 
Weight, kg 92 47 78 69 
25 Body Mass Index, kg!m
2* 25.5 19.2 21.6 24.4 
Fat,%* 32.3 28.7 13.5 22.4 
Fat, kg* 29.1 13.7 10.0 18.13 
Fat-free mass, kg* 61.1 34.0 64.3 50.8 
30 
The Lij parameters for human subjects were similar to 
those reported for cattle except for L2.1 which was lower for 
humans (0.18 in cattle versus 0.07 min-1 in humans). Table 
5 provides a summary of three studies: Rathmacher, J. A. et 
al., "Evaluation of muscle protein turnover in steers differing 
in mature size (1993), unpublished; Rathmacher, J. et al., 
'The use of compartmental models of3-methylhistidine flux 
to evaluate skeletal muscle protein turnover in implanted 
steers," J. Anim. Sci. (1993) 71:135 (Abstract); and Rath-
macher, J. A. et al., ''Technical Note: The use of a compart-
mental model to estimate the de novo production rate of 
Nt-methylhistidine in cattle," J. Anim. Sci. (1992) 
70:2104-2108. Based on the size of compartment 1, M1 has 
a mass similar to extracellular water space and M2 and M3 
are most consistent with intracellular pools of 3-methylhis-
tidine (fable 2). Muscle biopsy data from lambs (Rathma-
cher, J. A. et al. (1993), "Measurement of 3-methylhistidine 
production in lambs by using compartmental-kinetic analy-
sis," Brit. J. Nutrition 69:743-755) indicate that compart-
ments 2 and 3 appear to be muscle specific for 3-methyl-
histidine in muscle. 
The present study confirmed that model estimates of 
3-methylhistidine production correspond to urinary 3-meth- 35 
ylhistidine production. Means were not different when 
expressed on body weight basis or on urinary creatinine 
basis, but they were 16% higher than urinary estimates. 
Similar correlations were measured in cattle (Rathmacher, J. 
*Body composition was determined for each subject from the measurements 
of body density estimated by underwater weighing (Goldman, R. F. and 
Buskirk, E. R., "Body volume measurement by underwater weighing: 
description of a method," In: Techniques for Measuring Body Composition 
(Brozek, J. ed.) Washington, D.C.: Nat'lAcad. of Sciences (1961) p. 78-79). 
The percentage of body fat was estimated from body density by using the 
revised equation of Lohman et a!. (Lohman, T. G. et a!., "Bone and mineral 
measurements and their relation to body density in children, youth and 
adults," Hum. Bioi. (1984) 56:667--679). 
TABLE2 
Kinetic parameters of 3-methylhistidine metabolism 
and 3-methylhistidine model masses and mass transfer rates.* 
Subjects 
Parameter A B c D Mean SEt 
L,,., min-'; 0.0509 0.1573 0.0196 0.1372 0.0759 0.0686 
L,,2, min-I 0.0224 0.1505 0.0111 0.1887 0.0614 0.0944 
J..,,l> min-I 0.0048 0.0051 0.0024 0.0035 0.0041 0.0017 
I., . -1 0.0051 0.0141 0.0074 0.0148 0.0089 0.0074 
.2•mm 
!..,,3, min-I 0.0004 0.0017 0.0029 0.0016 0.0017 0.0008 
M., nmol . kg-1f 383 390 858 780 603 109 
M,, nmol · kg-1 952 421 1692 581 912 245 
M3 , nmol · kg-1 15856 3584 5070 7240 7938 2377 
u3, nmol . kg-!. min-1** 1.83 2.00 2.04 2.72 2.15 0.17 
R,,., nmol · kg-1• min-'tt 19.49 61.36 16.83 10694 51.15 18.37 
R1,2, nmol · kg-1· min-1 21.31 63.35 18.87 109.66 53.30 18.52 
Ro,., nmol · kg-1• min-1 1.83 2.00 2.04 2.72 2.15 0.17 
R3 ,2, nmol · kg-1• min-1 4.86 595 12.50 8.62 798 1.47 
R,,3 nmol · kg-'. min-1 6.69 595 14.55 11.34 19.63 1.75 
*The kinetic parameters for a 3-rompartment model of 3-methylhistidine metabolism are 
presented for each subject along with the mean and tstandard error. ;L,;, fractional transfer 
from compartment i to compartment j. §M;, mass of compartment i; **U3 , de novo 





Relationship of model parameters to urinacy 
3-methylhistidine production and body composition*. 
Correlation Coefficient P-value 
3-Methylhistidine production 
model to urinet 
Body composition to model parameters 
fat free mass to M2 t 
fat free mass to model 3MH§ 
fat mass to M3 











*Model is a 3-compartment model of 3-methylhistidine production. t3-Me-
thylhistidine production for model and urine have the units J.U110l · d-1 • :j:Fat 
free mass has the units of kg, and M2 is mass of compartment 2 in nmoles. 
§Model 3-methylhistidine is the estimate of production expressed as J.U110l · 
o 1 . **Fat mass has the units of kg, and M3 is the mass of compartment 3 in 
nmoles. 
EXAMPLE2 
Comparison of Human and Animal 3-methylhistidine Mod-
els. 
The differences between 3-methylhistidine metabolism in 
humans as found in Example 1 and other animals is shown 
in Table 5. For cattle, the same three-compartment model 
was used as described herein. With respect to sheep, the 
model differs from that shown in FIG. 1 in that de novo 
production of 3-methylhistidine is shown in compartment 2 
and additionally, exit from compartment 3 occurs as well as 
from compartment 1 into urine. With respect to swine, again, 
de novo production of 3-methylhistidine is shown in com-
partment 2, and exit to urine is from compartment 3. 
TABLE4 
Summacy of 3-methylhistidine metabolism 
as described by a 3-compartment model. 
Included are mass of compartments and mass transfer rates. 
Parameter Human Cattle* Pigst Sheep§ Dogs'{ 
n 4 36 20 36 5 
M1, nmol · kg-1** 603 806 1110 4693 3227 
M2 , nmol · kg-• 912 2106 2857 11634 7973 
M3 , nmol · kg-• 7938 7803 6151 16494 9261 
R,1, nmol · kg-1• min-' 51 103 247 928 319 
R12, nmol · kg-1• min-' 53 107 247 930 329 
R32, nmol · kg-'· min-1 7.9 5.4 37 84 56 
R,, nmol · kg-1• min-• 9.6 9.6 32 80 56 
R,1, nmol· kg-1• min-1 2.2 4.2 NA 1.4 9 
Ro,, nmol · kg-1• min-' NA NA 5.0 5.7 NA 
3MH Production, 3.1 6.2 7.2 10.1 12 
jJlilOl · kg-1.d-1 
*Data obtained from cattle experiments (reported in Rathmacber, J. A. et a!. 
(1992), "Technical Note: the use of a compartmental model to estimate the de 
novo production rate of N-methylhistidine in cattle," J. Anim. sci. 
70:2104-2108; Rathmacber, J. et a!., "'The use of compartmental models of 
3-methylhistidine flux to evaluate skeletal muscle protein turnover in 
implanted steers," J. Anim. Sci. (1993) 71:135 (Abstract); Rathmacher, J. A. 
eta!., "Evaluation of muscle protein turnover in steers differing in mature size 
(1993), unpublished). 
tData obtained from finishing swine experiment (Rathmacher, J. A. et a!., 
"Estimation of 3-methylhistidine production in pigs by compartmental analy-
sis," J. Anim. Sci (1995) In Press). 
§Data summarized from Rathmacher, J. A., "Comparative evaluation of 
muscle proteolysis by a compartmental model of 3-methylhistidine," Ames: 
Ph. D. Thesis, Iowa State University, 1994. 
'!Data obtained from dog experiment (Rathmacher, J. A. eta!., "A compart-
mental model to measure 3-methylhistidine production in dogs following 




Summacy of 3-methylhistidine metabolism 
as described by a 3-compartment model. 
Included are mass of compartments and mass transfer rates. 
Parameter Human Cattle* Pigst Sheep§ Dogs'{ 
**M; = compartment mass i; R = mass transfer rate between compartment j 
and i; 3-methylhistidine production was obtained from the model (See FIG. 
10 4A, 4B, and 4C for model illustration). 
Urinary 3-methylhistidine may be used in cattle and 
humans as an index of muscle protein breakdown but is 
invalid for use in pigs and lambs. 3-methylhistidine is 
produced in these species but is not quantitatively excreted 
15 in the urine. Previously, in validating urinary 3-methylhis-
tidine as an index of muscle proteolysis, researchers have 
injected 14C-3-methylhistidine intravenously and recovered 
the tracer in urine but have never described its decay in 
plasma. In constructing the 3-compartment model, we kept 
20 in mind known physiology of 3-methylhistidine. It has been 
established that there are pools of 3-methylhistidine in 
plasma, in other extracellular fluid pools, within muscle and 
in other tissues. The primary fate of 3-methylhistidine in 
humans, cattle and dogs is into urine (model exit from 
25 compartment 1), but in sheep and pigs there is a balenine 
pool in muscle that accumulates over time (model exit from 
compartment 3). The kinetic data were initially fitted to three 
exponential terms, indicating the possibility of a three com-
partment model. Based on these results a series of linear 
30 time-invariant compartmental models were constructed. 
Model code 10 of SAAM was used and the models were 
based on a set of linear differential equations having constant 
coefficients. Based on comparison of fits, a 3-compartment 
model was the best model to describe the metabolism of 
35 3-methylhistidine; however, 2- and 4-compartment models 
as well as other configurations were also evaluated. A 
3-compartment model provided the best fit and was signifi-
cantly different from a 2-compartment model (P<0.05); 
there was no advantage to adding a fourth compartment. 
40 Next, studies were designed utilizing the decay of a tracer of 
3-methylhistidine over a 5-day period. From these data a 
compartmental model in lambs was developed and a steady 
state production rate of 3-methylhistidine was estimated. 
However, with most isotopic models it is difficult to validate 
45 them because there are no non-isotopic methods to validate 
the isotope models. The approach taken to validate the 
3-methylhistidine model in sheep was comparative, using 
species in which urinary 3-methylhistidine is a valid index 
of muscle proteolysis. Studies in cattle, humans and dogs 
so were used to compare the estimates of 3-methylhistidine as 
estimated from the model to urinary 3-methylhistidine pro-
duction. 
The major accomplishments of the experiments were: (1) 
isotopic decay of a tracer of 3-methylhistidine can be 
ss described by a 3-compartment model in sheep and pigs 
where urinary 3-methylhistidine is an invalid index of 
muscle proteolysis; (2) 3-methylhistidine production as esti-
mated by the model in humans, cattle and dogs was quali-
tatively similar to urinary 3-methylhistidine production; (3) 
60 a minimall-compartmental model was developed based on 
the terminal slope of the model; and ( 4) model parameters 
and the steady state compartment mass and fluxes as deter-
mined by the model are related to muscle mass. 
There are three assumptions that must be accepted when 
65 using linear compartmental models. First, the volume or 
mass of the compartment is assumed to remain constant. 
Secondly, the compartments are well-stirred; that is, when 
5,628,328 
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you sample a compartment, a representative sample of the 
entire compartment is taken. Finally, the rate constants 
remain constant. The 3-methylhistidine model in general 
also has specific assumptions: (1) 3-methylhistidine is not 
reutilized to a significant extent as there is no tRNA for 
3-methylhistidine; (2) the precursor pool does not change; 
the myofibrillar protein-bound 3-methylhistidine does not 
change with the experimental conditions. There is some 
indication that the pool increases shortly after birth. Our data 
would indicate that neither pharmacological manipulation 
nor dietary manipulation change the concentration in skel-
etal muscle. However, there may be some difference 
between muscles (longissimus dorsi vs. semitendinosus); (3) 
3-methylhistidine is quantitatively excreted in the urine or, 
if metabolic products of free 3-methylhistidine do occur, 
they are accounted for in the model. This is true for humans, 
cattle and dogs but not for sheep and pigs. In sheep and pigs 
a large proportion is retained in muscle as balenine but the 
model was adjusted to explain this process; ( 4) renal absorp-
tion does not change or is similar between treatments. This 
may be one explanation why sheep and pigs do not quan-
titatively excrete 3-methylhistidine in the urine. These spe-
cies may selectively reabsorb 3-methylhistidine; (5) no 
3-methylhistidine in the diet or, if present, 3-methylhistidine 
calculations must be corrected for dietary 3-methylhistidine; 
(6) the primary source of 3-methylhistidine is from skeletal 
muscle myofibrillar protein. This assumption has caused the 
most controversy between researchers. On an organ basis, 
skeletal muscle contains more than 90% of the protein-
bound 3-methylhistidine. 
TABLE 5 
Comparison of 3-methylhistidine kinetic parameters. 
Urinary 
18 
novo production of 3-methylhistidine could be placed as an 
entry into compartment 2 and an identical rate calculated. 
The compartment identity of compartment 2 and 3 is intra-
cellular pools of 3-methylhistidine. The metabolic form of 
5 3-methylhistidine in these compartments may not be iden-
tical nor is the identity of compartment 2 or 3 for one species 
the same identity for another species (i.e., cattle vs. sheep). 
The models also depict differences in the route by which 
3-methylhistidine exits the system. In cattle, humans and 
10 dogs, 3-methylhistidine is quantitatively excreted in the 
urine as illustrated by the exit from compartment 1. This 
urinary exit has been confirmed by comparison of urinary 
excretion of 3-methylhistidine and model calculated values, 
whereas sheep excrete only 15% of total daily 3-methylhis-
15 tidine produced in the urine and pigs 1.5%/d. Therefore, 
accurate accounting of 3-methylhistidine production in 
sheep and pigs requires an exit out of the system from 
compartment 3. This exit accounts for appreciable loss of 
3-methylhistidine into a balenine "sink" which turns over 
20 slowly or not at all during the time frame of the study. 
In general, each species exhibited a similar exponential 
decay curve characterized by rapid decay over the first 2-3 
hours, followed by a slower decay through 12 hours, and a 
steady state decay over the remainder of the study. The 
25 decays of tracer are representative of the models used. 
Cattle, humans and dogs exhibit very similar decays while 
sheep and pigs are very different. 
Table 5 lists the model parameters, fractional transfer 
rates (Lii from compartment j to i). The fractional standard 
deviation of the parameters ranges from 5 to 50% and in 
3MH loss, Fractional transfer rate, min-'• 
Species Number %of total ~-' L,.2 1..,,2 ~,3 Lo,3 Lo,I 
Cattle 39 100 .18 .06 .003 .002 NA** .006 
HIDllans 4 100 .08 .06 .009 .002 NA .004 
Dogs 5 100 .11 .06 .006 .008 NA .02 
Swine 20 1 .23 .09 .014 .006 .0009 NA 
Sheep 40 17 .21 .08 .007 .005 .0004 .0003 
*Fractional transfer rate (L1J) from compartment j to i. 
**Not Applicable. 
Tables 4 and 5 are summaries of the efforts to model 
3-methylhistidine metabolism using a 3-compartment model 
in humans, cattle, and dogs which quantitatively excrete 
3-methylhistidine in urine, as compared to sheep and swine 
which do not quantitatively excrete 3-methylhistidine into 
urine. FIG. 4 is a comparison of model structures between 
the species. The diversity of models between cattle, dogs and 
humans and sheep and pigs reflects differences in known 
physiology. In each species the tracer is injected into com-
partment 1 which, based on size (volume and mass), is 
similar to plasma and extracellular water space. Compart-
ment 1 was the sampling compartment and the compartment 
from which the steady state calculations were initiated. All 
models for each species can be resolved by sampling only 
plasma, except in sheep-the model in FIG. 4 required the 
sampling of plasma and urine. However, the sheep model 
can be resolved from plasma kinetics of 3-methylhistidine if 
the rate of exit from compartment 1 is fixed. From the steady 
state calculations the de novo production of 3-methylhisti-
dine was obtained into compartment 3 for humans, cattle and 
dogs and into compartment 2 for sheep and pigs. The de 
general L2 1, L1 2 and L0 1 or L0 3 are solved with a higher 
precision than L3 ,2 and L;,3• Table 4 compares the compart-
50 ment masses and mass transfer rates between compartments 
for each species. Also listed is the de novo production rate 
calculated by the model in Table 4. An inlportant feature of 
these models is the description of 3-methylhistidine metabo-
lism within the body. The significance of mass transfer rates 
and compartment sizes is not fully understood. However, the 
55 model parameters and mass transfer rates may explain the 
failure of sheep and swine to quantitatively excrete 3-me-
thylhistidine in the urine. Three mechanisms may explain 
this failure of sheep and pigs to excrete 3-methylhistidine: 
(1) 3-methylhistidine transport between the compartments 
60 limits the excretion of 3-methylhistidine; (2) 3-methylhisti-
dine is avidly reabsorbed by the kidney; and (3) enzymatic 
conversion of 3-methylhistidine to balenine is enhanced. In 
comparison of data from Tables 4 and 5, the low rate of 
3-methylhistidine excretion in sheep and swine is not due to 
65 inlpaired transfer of 3-methylhistidine out of and between 
compartments. Cattle appear to have lower exchange of 
3-methylhistidine between tissues despite near quantitative 
5,628,328 
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that the plasma concentration of 3-methylhistidine was 
negatively correlated to the mass of muscle. Stepwise mul-
tiple regression was conducted on model parameters and live 
body weight to predict muscle mass; variables were added 
urinary excretion. The most likely reason for sequestering of 
3-methylhistidine in sheep and swine is that the kidneys are 
very efficient in conserving 3-methylhistidine, which in turn 
increases compartment size and plasma concentration and 
through mass action could increase the synthesis of balen-
ine. 
EXAMPLE3 
5 such that R
2 was maximized. The R2 was maximized at 0.74 
for a !-variable model and 0.99 for a 12-variable model. A 
representative model is presented to demonstrate the pre-
dictive power of the multiple regression equations. The best 
5-variable model is as follows: muscle mass (kg)=-22.7+ 
Comparison with Minimal Model. 
10 0.117 (plasma 3-methylhistidine, nmol/mL) +0.00000348 (mass of compartment 3, nmol) -0.000903 (mass transfer 
rate from compartment 2 to 3, nmollmin) +0.263 (weight of 
the pig) +0.705 (3-methylhistidine production, mol/kg/d) 
(R2=0.91, P<O.OOOl). A plot of predicted muscle mass 
A minimal model using 4-5 measurements and one com-
partment rather than three was evaluated. In the minimal 
model the three pools of the 3-compartment model were 
combined to form one homogeneous pool of 3-methylhisti-
dine, characterized by a de novo production into the body 
pool and one exit from the model. The kinetic data between 
720 and 4320 min was used for the analysis; this time frame 
corresponds to apparent linear steady state portion of the 
decay curve. The limitation of the !-compartment model is 
the lost ability to described the entire metabolism of 3-me-
thylhistidine. Only the rate of proteolysis and a total pool 
size can be estimated. Similar results were obtained in dogs 
when comparing the complete model (3-compartment) to the 
minimal model. (Rathmacher, J. et al., "The use of com-
partmental models of 3-methylhistidine flux to evaluate 
25 
skeletal muscle protein turnover in implanted steers," J. 
Anim. Sci. (1993) 71:135.) However, in cattle the minimal 
model estimates of 3-methylhistidine production were 30% 
higher, but the estimates of 3-methylhistidine production 
were highly correlated (r=0.93, P 0.0001). 
15 compared to observed muscle mass is presented in FIG. 5. A similar approach was taken with the human data set to 
predict fat free mass. The model included the variables M2 
(compartment mass of pool2) and U3 (estimate of proteoly-
sis) which is de novo 3-methylhistidine production calcu-
20 lated in the model. 
EXAMPLES 
Prediction of muscle mass in humans using model param-
eters of a 3-compartment model of 3-methylhistidine. 
Eight human volunteers were studied: 3 females and 5 
males, age 24.9±2.9 years (range 22.0-31.0), weight 
69.1±11.2 kg (range 48.4 to 80.6). Subjects were given an 
intravenous dose of 3-[methyl-2H3]-methylhistidine (0.2 
J.llllOl/kg of body weight), which was followed by serial 
EXAMPLE4 
Prediction of muscle mass from the 3-methylhistidine 
model. 
30 blood samples at 1, 2, 5, 10, 30, 45, 90, 150, 210,330, 510, 
720, 1440, 2880 and 4320 min postinjection. Subjects were 
studied at State University of New York, Stonybrook, Stony-
brook Health Sciences Center, School of Medicine, Depart-
ment of Surgery, Stonybrook, N.Y. 
From the three-compartment model of 3-methylhistidine 
metabolism, the model parameters (Lij), steady state pool 
size of these compartments (M;), steady state mass transfer 
rates (Rij), and an estimate of proteolysis (Ui) were calcu-
lated. The first pool is the compartment where the tracer is 
introduced and has the volume and mass comparable to 
plasma plus extracellular fluid. Compartments 2 and 3 are 
intracellular pools of 3-methylhistidine. Greater than 90% of 
3-methylhistidine bound to protein is found in muscle and 
when the myofibrillar protein is degraded, the 3-methylhis-
tidine enters the tissue compartments. Therefore, the amount 45 
of free 3-methylhistidine located in the tissue compartments 
should be proportional to muscle mass of humans and 
animals. This relationship would be expected since this 
compartment is an intracellular pool of free 3-methylhisti-
dine in primarily muscle and as skeletal muscle becomes 50 
larger, this pool of 3-methylhistidine should become larger. 
This relationship would hold true given that the de novo 
production of 3-methylhistidine, fractional and mass transfer 
rates, and 3-methylhistidine concentration remained rela-
tively constant. However, this is obviously not true. There- 55 
fore, these known variables should be included in any 
predictive model. This approach has been taken in subse-
quent analysis of the data in pigs and in humans. In Table 7, 
we have correlated the compartment mass of a particular 
species with muscle. In addition, other model parameters 60 
have been found to be indicative of muscle mass. In the first 
example with pigs, the mass of compartment 3 was posi-
tively correlated with muscle mass. In addition, the mass 
transfer rate from compartment 2 to 3 was negatively 
correlated with muscle mass. The final example for pigs is 
35 The tracer to tracee ratio and the concentration of 3-me-
thylhistidine was determined by GC/MS as previously 
described. The kinetic data were modeled according to the 
previously described 3-compartment model. Results of the 
modeling are set forth in Table 8. Muscle mass (kg) was 
40 determined by prompt gamma neutron-activation at the 
Medical Research Center, Brookhaven National Laboratory, 
Upton, N.Y. These data were used in a multiple regression 
procedure (stepwise multiple procedure of SAS) in which R2 
was maximized. 
TABLE 7 
Relationship between model compartments and muscle. 
Correlation 
Correlation coefficient r P-value 
M3 vs. kg of muscle, 0.59 0.006 
pigs 
R,,2 vs. kg of muscle, -o.64 0.002 
pigs 
Plasma 3MH vs. kg of -o.52 0.02 
muscle, pigs 
Multiple regression 095 0.0001 
model vs. kg muscle, 
pigs 
M2 vs. muscle, humans 091 0.09 
M3 vs. muscle, humans 0.56 0.44 
u3 vs. muscle, humans 0.74 0.026 
L;,,1 vs. muscle, humans -o.92 0.08 
Multiple regression 0.98 0.1 





































































L.; =Fractional transfer rate from compartment j to i. 
K; = Proportionality c 





















U1 =de novo 3-methylhistidine production (nmol· min) from compartment ito j (nmol· min), 
MUSC =skeletal muscle calculated as fOllows: (19.251BK-1BN)/38.34 
1BN = Total body nitrogen 
1BK = 'lbtal body potassium 
LBM =Lean body mass (Fat Free) 
PL3MH =Plasma 3-methylhistidine concentration (mmol · mL). 
wr = Body weight (kg) 
22 
Stepwise multiple regression was computed by using the 35 AS-variable model used was: Muscle (kg)=-30.88-31.94 
above variables supplied from the 3-compartment model of (Lz,1)-t467 .78 (L3'.!)+ 1.08 (wt)-0.095 (U3)-Q.00122 
3-methylhistidine metabolism; regression models ranged (R2 1) (P=O.OOS, R =0.99); 
from 1- to 7 variable models with R2 from 0.91 to 0.99, A 6-viu'iable model used was: Muscle (kg)=-33.50+1.13 
respectively. Muscle in humans can be predicted with a high (wt)-23.01 (Lz,1)-373.03 (L0,1);+-365.28 (L3,2)+0.0744 
degree of accuracy (standard error of 0.28 kg). For example: 40 (R2,1)-Q.0760(Rl,2) (P=O.Ol, R =99); 
A 2-variable model used was: Muscle (kg)=-37.86+0.95 A 7-variable model used was: Muscle (kg)=-29.89+1.16 
3
(wt) ~ob.1oo183(R12,1) (P=0.0003, R2=0.96); ~~~ooiis~~~~~,;~ -x~6~5~3X4.53(L3,2)-A -vana e mode used was: Muscle (kg)=-40.76+1.08 The variables are defined as ill Table 8. ' 
(wt)-607.71 <Lo,l)-Q.002(Rl,z) (P=0.001, R2=0.98); 
45 Table 9 sets forth the regression models showing maxi-A 4-variable model used was: Muscle (kg)=-39.52+1.10 mum R2improvement for the dependent variables. 
(~)+15.82(L2.1)-884.81(L0, 1)-0.003(R2, 1 ) (P=0.002, Table 10 sets forth a representative 5-variable model in 
R =0.99); detail. 
TABLE9 
Regression Models 
Maximwn R2 Improvement for Dependent Variables 
Best !-variable model futmd: 














Parameter Standard 'JYpe TI 






-31.79100899 6.80239450 179.42145497 21.84 0.0034 
0.79900212 0.09729156 554.03206417 67.44 0.0002 





Maximum R 2 Improvement for Dependent Variables 
Best 2-variable model fotmd: 
Step 2 Variable R2,1 entered R-square = 0.95996839_ 
DF Sum of Squares Mean Square F 
Regression 2 579.16812909 289.58406455 59.95 
Error 5 24.15187091 4.83037418 
Total 7 603.30000000 
Parameter Standard Type II 
Variable Estimate Error Sum of Squares F 
IN'IERCEP -37.85625493 5.85478579 201.94543925 41.81 
wr 0.95988723 0.10266494 422.25705563 87.42 
R,,, -o.00183124 0.00080276 25.13606493 5.20 
Bounds on condition number: 1.893662, 7.57465 
Best 3-variable model fotmd: 
Step 3 Variable wt entered R-square = 0.97321964 












Parameter Standard TYPe II 














Step 4 Variable R2,1 Removed R-square = 0.97635829 
Variable R1,2 Entered 






Regression 3 589.05648123 1%.35216041 55.06 
Error 4 14.26351877 3.56587969 
Total 7 603.32000000 
Parameter Standard Type II 
Variable Estimate Error Sum of Squares F 
IN'IERCEP --40.75748032 5.33097710 208.43358%4 58.45 
wr 1.08399144 0.11469893 318.49282168 89.32 
Lo .• -607.70936499 359.68195412 10.17937811 2.85 
R,,2 -o.00214213 0.00071730 31.80222100 8.92 
Bounds on condition number: 3.201777, 21.29248 
Best 4-variable model fotmd: 
Step 5 Variable L,,1 Entered R-square = 0.99070888 
DF Sum of Squares Mean Square F 
Regression 4 597.714481% 149.42862049 79.97 
Error 3 5.60551804 1.86850601 
Total 7 603.32000000 
Parameter Standard TYPe II 
Variable Estimate Error Sum of Squares F 
IN'IERCEP -39.81660277 3.88363891 196.40168878 105.11 
wr 1.12191046 0.08487587 326.46931089 174.72 
L,,, 13.30894179 6.18275399 8.65800073 4.63 
Lo,, -933.37777826 301.12952196 1795158271 9.61 
R,.2 -o.00316832 0.00070489 37.74934146 20.20 
Bounds on condition number: 3.795361, 50.6051 
Step 6 Variable R1,2 Removed R-square = 0.99124272 
Variable R,,1 Entered 
DF Sum of Squares Mean Square F 
Regression 4 598.03655751 149.50913938 84.89 
Prob>F 
0.0003 




Prob > F 
0.0013 






















































BoWlds on condition number: 4.083871, 52.13148 
Best 5-variable model fonnd: 
Step 7 Variable L;,,2 &t«od R-square = 0.99297290 



















Parameter Standard 'TYpe TI 




















Step 8 Variable Lo,1 Removed R-square = 0.99795894 
Variable U3 Entered 








Regression 5 602.08858510 120.41771702 195.58 
Error 2 1.23141490 0.61570745 
Total 7 603.32000000 
Parameter Standard 'JYpeTI 
v.rriable Estimate Error Sum of Squares F 
IN'IERCEP -30.88073963 2.42520239 99.82833369 162.14 
wr 1.08775288 0.06337577 181.37956823 294.59 
L,,, -31.93939487 15.05496627 2.77120212 4.50 
L;,,2 467.77 525419 103.66319961 12.53717468 20.36 
u3 -0.09259734 0.02660010 7.46113553 12.12 
R2,1 -0.00122401 0.00075528 1.61706341 2.63 
BoWlds on condition number: 76.77743, 902.2671 
Best 6-variable model fonnd: 
Step 9 Variable Lo,1 Entered R-square = 0.99994505 
DF Swn of Squares Mean Square F 
Regression 6 603.28684838 100.54780806 3032.97 
Error 1 0.03315162 0.03315162 
Total 7 603.32000000 
Parameter Standard 'JYpeTI 
v.rriable Estimate Error Sum of Squares F 
IN'IERCEP -33.50363960 0.71205189 73.39481615 221391 
wr 1.13428105 0.01661790 154.45216308 465896 
L,,, -23.038877 64 3.79412210 1.22237575 36.87 
Lo,! -372.63876382 6198180975 1.19826329 36.14 
L;,,2 365.42672310 29.46884753 5.09775549 153.77 
u3 -0.07 609328 0.00675525 4.20643725 126.88 
R,, -0.00167249 0.00019047 2.55605769 77.10 
BoWlds on condition number: 91.96439, 1381.858 














































Maximwn R2 Improvement for Dependent Variables 
Variable R1,2 Entered 
Prob> 
DF Swn of Squares Mean Square F F 
Regression 6 603.28897530 100.54816255 3240.91 0.0134 
Error 1 0.03102470 0.03102470 
Total 7 603.32000000 
Parameter Standard 'JYpe II 
Variable Estimate Error Swn of Squares 
INIERCEP -33.49983500 0.68895580 73.35170746 
wr 1.13413092 0.01606923 154.54113534 
L,,, -23.01024937 3.66715320 1.22149631 
Lo .• -373.02799394 59.94449237 1.20141180 
L,,2 365.27810472 28.48902405 5.10034736 
L,,, 0.07437503 0.00668546 3.83971895 
R,.2 -o.07604852 0.00652946 4.20856417 
Bounds on condition number: 20448.67, 241107.8 
Best 7-variable model found. 
Step 11 Variable M3 Entered R-square = 1.0000000 
DF Swn of Squares Mean Square 
Regression 7 603.32000000 
Error 0 0.00000000 
Total 7 603.32000000 
Parameter Standard 









Bounds on condition nwnber: 81284.64, 1138603 
No further improvement in R-square is possible. 
86.18857143 
TYPe II 



















F Prob > F 
F Prob >F 
Representative 5-variable model. 
Analysis of Variance 
Source DF Swn of Squares Mean Square FValue 
Model 5 602.08859 120.41772 195.576 
Error 2 1.23141 0.61571 
C Total 7 603.32000 
RootMSE 0.78467 R-square 0.9980 
Dep Mean 23.45000 Adj R-sq 0.9929 
c.v. 3.34614 
Parameter Estimates 
Parameter Standard TforHO: 
Variable DF Estimate Error Parameter = 0 
INIERCEP -30.880740 2.42520239 -12.733 
L,,, -31.939395 15.054%627 -2.122 
L,,2 467.775254 103.66319961 4.512 
u3 -o.092597 0.02660010 -3.481 
R,,, -o.001224 0.00075528 -1.621 










Dep Var Predict Std Err Lower 95% Upper 95% Lower 95% Upper 95% 
28 
5,628,328 
Obs MUSC Value 
1 14.4000 14.6090 
2 27.2000 27.1574 
3 28.5000 29.0651 
4 30.1000 29.7929 
5 31.4000 31.4522 
6 32.6000 32.4646 
7 9.0000 9.4179 
8 14.4000 13.6407 
Swn of Residuals 
Swn of Squared Residuals 
Predicted Resid SS (Press) 
29 
TABLE 10-continued 























Predict Predict Residual 
9.8849 19.3332 -0.2090 
22.3946 319202 0.0426 
24.7236 33.4067 -0.5651 
25.3978 34.1880 0.3071 
27.5168 35.3876 -0.0522 
27.7361 37.1931 0.1354 
4.8197 14.0162 -0.4179 
9.4670 17.8144 0.7593 
This invention has been described with respect to specific 
embodiments. Equivalent methods to those described will be 
readily apparent to those skilled in the art and are included 
of 3-methylhistidine in compartment 1, and the mass trans-
20 fer rate between compartments 3 and 2. 
within the scope of the appended claims. 
We claim: 
7. The method of claim 1 wherein said marker is 
D3-methylhistidine. 
8. The method of claim 1 wherein said marker is admin-
1. A method for determining muscle mass in a human istered in an amount between about 0.2 nmoVkg body 
subject comprising: 25 weight and about 0.8 nmoVkg body weight. 
(a) administering to said subject a known amount of a 9. The method of claim 1 wherein said marker is admin-
metabolic marker for 3-methylhistidine; istered intravenously. 
(b) periodically removing blood or urine samples from 10. The method of claim 1 wherein said marker is 
said subject; administered orally. 
(c) measuring the amount of said marker and of 30 11. The method of claim 1 wherein said blood or urine 
3-methylhistidine in each such sample; samples are taken over the period required to substantially 
(d) generating a three-compartment mathematical model reach steady state. 
from said measurements comprising numerical values 12. The method of claim 1 wherein said blood or urine 
for the fractional transfer rates in and out of said samples are taken over a period of between about 48 and 
compartments, numerical values for the mass of 35 about 72 hours. 
3-methylhistidine in each compartment, and numerical 13. The method of claim 1 wherein at least about 14 said 
values for the mass transfer rates in and out of said blood or urine samples are taken. 
compartments; 14. The method of claim 1 wherein said amounts of 
(e) calculating muscle mass as a function of the numerical marker and 3-methylhistidine are measured by gas chroma-
value of at least one of said values and the total body 40 tography mass spectroscopy. 
weight of the subject. 15. The method of claim 1 wherein said mathematical 
2. The method of claim 1 wherein total body weight of the model is generated using the SAAM computer program. 
subject is obtained and muscle mass is calculated as a 16. The method of claim 2 wherein said calculation of 
function of total body weight and the numerical value of muscle mass as a function of mass of 3-methylhistidine in 
compartment 2. 45 compartment 2 and body weight is made using the equation: 
3. The method of claim 1 wherein muscle mass is calcu-
lated as a function of the numerical value of the mass of 
3-methylhistidine in compartment 2, and of the fractional 
transfer rate between compartment 1 of said model and 
urine. 
4. The method of claim 1 wherein total body weight of the 
subject is obtained and muscle mass is calculated as a 
function of total body weight, the numerical value of the 
mass of 3-methylhistidine in compartment 2, and the frac-
tional transfer rate between compartment 1 of said model 
and urine. 
5. The method of claim 1 wherein total body weight of the 
subject is obtained and muscle mass is calculated as a 
function of total body weight, the mass of 3-methylhistidine 
so 
55 
in compartment 2, the fractional transfer rate between com- 60 
partment 1 of said model into urine, and the mass transfer 
rate from compartment 2 to compartment 1. 
6. The method of claim 1 wherein total body weight of the 
subject is obtained and muscle mass is calculated as a 
function of total body weight, the fractional transfer rate 65 
between compartments 2 and 1, the fractional transfer rate 
between compartment 1 of said model into urine, the mass 
Muscle mass (kg)=-31.96+0.0000027(M2}t{).80 (wt) 
where 
M2=the mass of 3cmethylhistidine in compartment 2 
(nmol) and wt=body weight (kg). 
17. The method of claim 3 wherein said calculation of 
muscle mass is made as a function of both the numerical 
value of 3-methylhistidine in compartment 2 and of the 
fractional transfer rate between compartment 1 of said 
model and urine using the equation: 
Muscle mass (kg)=-9.90+3039.5(L0,1}t{).00015S(M2) 
where 
L0,1=the fractional transfer rate from compartment 1 into 
urine (min-1) and M2=the mass of 3-methylhistidine in 
compartment 2 (nmol). 
18. The method of claim 4 wherein said calculation of 
muscle mass is made as a function of total body weight of 
the subject, the mass of 3-methylhistidine in compartment 2, 
and the fractional transfer rate between compartment 1 of 
said model and urine using the equation: 
5,628,328 
31 32 
Muscle mass (kg)=-32.39-0.00035(M2)-783.194(L0 ,1)+0.927 (Wt) 
where 
M2=the mass of 3-methylhistidine in compartment 2 
(nmol), L0.1=the fractional transfer rate of compart-
ment 1 into urine (min-1) and wt=body weight (kg). 
19. The method of claim 5 wherein said calculation of 
muscle mass is made as a function of total body weight, the 
mass of 3-methylhistidine in compartment 2, the fractional 
transfer rate between compartment 1 of said model into 10 
urine, and the mass transfer rate from compartment 2 to 
compartment 1, using the equation: 
20. The method of claim 6 wherein said calculation of 
muscle mass is made as a function of total body weight, the 
mass of 3-methylhistidine in compartment 1, the fractional 
transfer rate between compartments 2 and 1, the fractional 
5 transfer rate between compartment 1 and urine, and the mass 
transfer rate between compartments 3 and 2, using the 
where 
Muscle mass (kg)=-40.16-0.000031(M2)-1000.69(L0,1)-
0.0021(R1,2)+ 1.15 (wt) 
15 
M2=the mass of 3-methylhistidine in compartment 2 
(nmol), Lo 1=the fractional transfer rate between com-
partment l of said model into urine (min-1), R1•2=the 20 
mass transfer rate from compartment 2 to compartment 
1 (min-1 1), and wt=body weight (kg). 
equation: 
where 
Muscle mass (kg)=-22.02-255.13(L1,2)-2498.4(L0 ,1)-
0.000579(M1)+0.00486(R2.3)+ 1.27 (wt) 
L1•2=the fractional transfer rate between compartments 2 
and 1 (min-1), Lo 1=the fractional transfer rate from 
compartment 1 into urine (min-1), M1=the mass of 
3-methylhistidine in compartment 1 (nmol), ~.3=the 
mass transfer rate between compartments 3 and 2, and 
wt=body weight (kg). 
* * * * * 
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It is certified that error appears in the above-indentified patent and that said Letters Patent is hereby 
corrected as shown below: 
In Column I, lines 3-6, delete "This invention was made, at least in part, with funding from the National 
Institutes of Health (Grants DK-26657, DK-20593, RR-00095 and DK-43290) and the United States 
Government may have certain rights therein." 
In Column 1, line 31, delete "Of" and replace with --Of--. 
In Column 3, line 19, delete "interindividual" and replace with --inter-individual--. 
In Column 7, line 41, delete the space which appears before "2Hrmethyl". 
In Column 7, line 42, delete "13C" and replace with -- 13c--. 
In Column 12, line 49, delete "p.mol-kg-1-d-1" and replace with --p.mol·kg- 1-d-1--. 
In Column 12. line 50, delete "p.mol·mg-• and replace with --Jlmol·mg-1--. 
In Column 12. line 51, delete "1).". 
In Column 14, Table 2, last line of ''Mean" column, delete "19.63" and replace with --9.63--. 
In Column 15, Table 4, tinalline under "parameter" column, delete "p.mol·kg-1.d-1" and replace with--
J1mol·kg-1·d-1--. 
In Column 21, Table 8, fourth line of "Mean" column, delete "0.00722S" and replace with --0.007225--. 
In Column 21, Table 8, eighth line of "Sum" column, delete "2819S9" and replace with --281959--. 
In Colunm 23 (Table 9-continued) line 9, delete "603.30000000" and replace with --603.32000000--. 
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